This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Illumina discloses terms of settlement with Chinese rival BGI Genomics

( July 19, 2022, 11:54 GMT | Official Statement) -- MLex Summary: US biotech company Illumina has disclosed in a US regulatory filing the terms of a July 14 settlement of antitrust and intellectual property disputes with Chinese competitor BGI Genomics. It involved Illumina paying BGI’s subsidiary Complete Genomics $325 million and receiving in return from BGI a fully paid-up license to use its “2-channel” technology. BGI received from Illumina a fully paid-up license to certain of its “image mix” patents until their expiration. The parties also agreed to a litigation standstill for US patent and antitrust actions until Oct. 1, 2025. The settlement's terms don't apply to any IP of Grail that relates to multi-cancer early detection.Statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login